Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy

Published:2013-10-17 Issue:22 Volume:105 Page:1729-1737
ISSN:0027-8874
Container-title:JNCI Journal of the National Cancer Institute
language:en
Short-container-title:JNCI Journal of the National Cancer Institute

Author:

Halabi S.,Lin C.-Y.,Small E. J.,Armstrong A. J.,Kaplan E. B.,Petrylak D.,Sternberg C. N.,Shen L.,Oudard S.,de Bono J.,Sartor O.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/105/22/1729/7676125/djt280.pdf

Reference24 articles.

1. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

2. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

3. Abiraterone and Increased Survival in Metastatic Prostate Cancer

4. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

5. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Cited by 143 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Survival by first‐line therapy and prognostic group among men with metastatic castration‐resistant prostate cancer;Cancer Medicine;2024-06

2. Prostate cancer brain metastases: Monitoring response to treatment with PSMA PET/CT;Radiology Case Reports;2024-06

3. Bellmunt risk score as a survival predictor in patients with metastatic castration‐resistant prostate cancer;The Prostate;2024-05-15

4. The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide;Clinical Cancer Research;2024-01-18

5. Identification of the shared gene signature and biological mechanism between type 2 diabetes and colorectal cancer;Frontiers in Genetics;2023-10-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3